In these brief videos, noted nephrologist, Dr. Daniel Coyne, discusses the importance of managing phosphorus levels, and how treatment with Velphoro can make a difference for chronic dialysis patients.

Real-world experience with Velphoro

Dr. Coyne discusses how a switch to Velphoro doubled the percentage of patients that achieved phosphorus goal in a real world analysis1
(02:23)

Reducing the daily pill burden

Dr. Coyne discusses the value of low pill burden and flexible administration in helping patients remain on treatment1
(00:55)

It’s time for a different approach

Dr. Coyne summarizes how Velphoro can help dialysis patients take control of managing their phosphorus levels1
(01:08)

Learn more about how Velphoro can help control serum phosphorus levels

REGISTER >

Reference:
1. Coyne DW et al. Clin Nephrol. 2017;88(8):59-67.

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at
1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.
 

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451